Balyasny Asset Management
BOLD

Balyasny Asset Management’s Boundless Bio BOLD Stock Holding History

Balyasny Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$428K – 3208
2024
Q1 		$428K Buy
+30,000
New +$428K ﹤0.01% 2110

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Balyasny Asset Management's BOLD Position: Q2 2024 in Review

Balyasny Asset Management sold out of Boundless Bio (BOLD) in Q2 2024, closing a stake of 30,000 shares — an estimated $428K sold.

Balyasny Asset Management first reported a position in BOLD in Q1 2024 and held it in 1 quarter. The position peaked at $428K in Q1 2024. 47 funds tracked by Wall St. Rank hold BOLD as of Q2 2024.

  • Balyasny Asset Management reported no remaining Boundless Bio position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 30,000 Boundless Bio shares in Q2 2024, an estimated $428K.
  • Balyasny Asset Management first reported a position in Boundless Bio in Q1 2024 and held it in 1 quarter.
  • Balyasny Asset Management's Boundless Bio position peaked at $428K in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.